Experiences with
Ibrutinib2,003 public posts
Want to take advantage of all our features? Just log in!
or
Update on Novel B-Cell Receptor Signaling Inhibitors from NCCN 8th Annual Congress on Hematologic Malignancies
Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (Arzerra) and rituximab.
ASH 2013 - Dr Sharman's abstracts
The B cell receptor signaling pathway involves a sequence of enzymes that start with Syk (fostamatanib, GS-9973), goes to BTK (ibrutinib and CC-292), then on to PI3K (idelalisib). Antibody drug conjugates are another favorite topic of mine.
Dr Sharman's thoughts on the race for FDA Approval for Obinituzumab, Ibrutinib and Idelalisib
Following Gilead's announcement regarding Idelalisib: https://healthunlocked.com/cllsupport/posts/130204565/gilead-to-stop-phase-3-study-116-of-idelalisib-in-chronic-lymphocytic-leukemia-early-because-of-positive-risk-benefit
Dr Sharman summarises where things stand with Obinituzumab, Ibrutinib and Idelalisib
iwCLL 2013: Dr. Jan Burger on the Role of the Micro-Environment in CLL
While this is basic bench science, it is critical to understanding how many of the novel therapies such as idelalisib and ibrutinib work and how difficult it can be for traditional therapies to get rid of CLL deep in the nodes and marrow.
Dr Rick Furman interviewed at IWCLL by Patient Power
Furman explains how a leading treatment candidate, ibrutinib, works. [i]He also discusses whether there is concern that some patients may develop resistance to the drug and its effectiveness.
ABT-199 Trial experience in Australia
When I asked Andrew whether ABT-199 could help patients with Richter's Transformation, he responded that like Ibrutinib, it wouldn't work as a single therapy and in fact it had mostly stopped working when Richter's developed.
New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA
This is NOT an approval, it is the beginning of the approval process but only for two uses or indications... previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
http://online.wsj.com/article/PR-CO-20130829
FDA application made for Ibrutinib in refractory/relapsed CLL/SLL ONLY
Janssen Research & Development, LLC announced the submission of a New Drug Application for ibrutinib to the U.S.
Ibrutinib article includes info on leukaemia and lymphoma and how lymphocytes function
Interesting Gizmag article on Ibrutinib with some good background on how lymphocytes work and how CLL and MCL differ. (Ibrutinib trials were done on both).
http://www.gizmag.com/lymphoma-treatment-cancer-ibrutinib/28085/
It is worth looking through the associated pictures.
A Mechanism-Driven Treatment for Chronic Lymphocytic Leukemia?
Editorial
http://www.nejm.org/doi/pdf/10.1056/NEJMe1303054
Also published data on early ibrutinib trial...
Dr Sharman blogs on Cure for CLL & NHL?.... or just better control?
He observes that there have already been at least four cases of ibrutinib resistance and argues the case that a combined drug treatment will be necessary to avoid CLL/NHL developing resistance to new treatments.
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia...
This paper reviews the preclinical and clinical data for ibrutinib when used in the treatment of CLL. Recent studies showing the benefit of combination therapy using ibrutinib, monoclonal antibodies, and chemoimmunotherapy are also discussed.
http://www.dovepress.com/getfile.php?fileID=16102